The pharmacokinetics of slow-release procainamide

Procainamide was given to 20 patients with normal renal function as an i.v. bolus of 500 mg followed by 1.0 or 1.5 g eight-hourly by mouth in the form of a slow release preparation (Durules). 97.6 +/- 27.1 (SD)% of the oral procainamide was absorbed, the absorption half life being 1.54 h. The elimin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of clinical pharmacology 1978-12, Vol.14 (4), p.261-265
Hauptverfasser: Tilstone, W J, Lawson, D H, Campbell, W, Hutton, I, Lawrie, T D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 265
container_issue 4
container_start_page 261
container_title European journal of clinical pharmacology
container_volume 14
creator Tilstone, W J
Lawson, D H
Campbell, W
Hutton, I
Lawrie, T D
description Procainamide was given to 20 patients with normal renal function as an i.v. bolus of 500 mg followed by 1.0 or 1.5 g eight-hourly by mouth in the form of a slow release preparation (Durules). 97.6 +/- 27.1 (SD)% of the oral procainamide was absorbed, the absorption half life being 1.54 h. The elimination half life following the oral formulation was 6.0 +/- 0.8 h, compared to a mean of 3.4 +/- 0.4 h following i.v. administration. Elimination half life following i.v. administration was slightly related to acetylator status, being 2.75 +/- 0.9 h in fast acetylators, and 4.4 +/- 2.4 h in slow acetylators. This dependence on acetylator status was not seen in half life following oral administration. Total body clearance, steady state plasma procainamide and N-acetylprocainamide were not significantly dependent on acetylator status, although a few patients who are slow acetylators had unexpectedly low clearance and high steady state procainamide concentrations when given the higher dose.
doi_str_mv 10.1007/BF00560459
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_74329611</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>74329611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c281t-52116622ef14764d9c151726463adb484c26edf566f6dddd8c93bf992fd3b6193</originalsourceid><addsrcrecordid>eNpFkL9PwzAQhS3Er1BYmBk6MSAF7mznUo9QUUCqxFLmyLHPaiBpit0K8d8T1Apuecun93SfEJcItwhQ3j3MAAoCXZgDkaFWMkfQeCgyAIU5mRJOxVlK7wBYGFAn4riUhiRkAhdLHq-XNnbW9R_NijeNS-M-jFPbf-WRW7ZpAGLvbLOyXeP5XBwF2ya-2OdIvM0eF9PnfP769DK9n-dOTnCTFxKRSEoOqEvS3jgssJSkSVlf64l2ktiHgiiQH27ijKqDMTJ4VRMaNRLXu95h_HPLaVN1TXLctnbF_TZV5fCmIcQBvNmBLvYpRQ7VOjadjd8VQvWrp_rXM8BX-9Zt3bH_Q3c-1A9cPF3P</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>74329611</pqid></control><display><type>article</type><title>The pharmacokinetics of slow-release procainamide</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Tilstone, W J ; Lawson, D H ; Campbell, W ; Hutton, I ; Lawrie, T D</creator><creatorcontrib>Tilstone, W J ; Lawson, D H ; Campbell, W ; Hutton, I ; Lawrie, T D</creatorcontrib><description>Procainamide was given to 20 patients with normal renal function as an i.v. bolus of 500 mg followed by 1.0 or 1.5 g eight-hourly by mouth in the form of a slow release preparation (Durules). 97.6 +/- 27.1 (SD)% of the oral procainamide was absorbed, the absorption half life being 1.54 h. The elimination half life following the oral formulation was 6.0 +/- 0.8 h, compared to a mean of 3.4 +/- 0.4 h following i.v. administration. Elimination half life following i.v. administration was slightly related to acetylator status, being 2.75 +/- 0.9 h in fast acetylators, and 4.4 +/- 2.4 h in slow acetylators. This dependence on acetylator status was not seen in half life following oral administration. Total body clearance, steady state plasma procainamide and N-acetylprocainamide were not significantly dependent on acetylator status, although a few patients who are slow acetylators had unexpectedly low clearance and high steady state procainamide concentrations when given the higher dose.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/BF00560459</identifier><identifier>PMID: 729620</identifier><language>eng</language><publisher>Germany</publisher><subject>Biological Availability ; Delayed-Action Preparations ; Electrocardiography ; Half-Life ; Humans ; Kinetics ; Procainamide - administration &amp; dosage ; Procainamide - metabolism</subject><ispartof>European journal of clinical pharmacology, 1978-12, Vol.14 (4), p.261-265</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c281t-52116622ef14764d9c151726463adb484c26edf566f6dddd8c93bf992fd3b6193</citedby><cites>FETCH-LOGICAL-c281t-52116622ef14764d9c151726463adb484c26edf566f6dddd8c93bf992fd3b6193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/729620$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tilstone, W J</creatorcontrib><creatorcontrib>Lawson, D H</creatorcontrib><creatorcontrib>Campbell, W</creatorcontrib><creatorcontrib>Hutton, I</creatorcontrib><creatorcontrib>Lawrie, T D</creatorcontrib><title>The pharmacokinetics of slow-release procainamide</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>Procainamide was given to 20 patients with normal renal function as an i.v. bolus of 500 mg followed by 1.0 or 1.5 g eight-hourly by mouth in the form of a slow release preparation (Durules). 97.6 +/- 27.1 (SD)% of the oral procainamide was absorbed, the absorption half life being 1.54 h. The elimination half life following the oral formulation was 6.0 +/- 0.8 h, compared to a mean of 3.4 +/- 0.4 h following i.v. administration. Elimination half life following i.v. administration was slightly related to acetylator status, being 2.75 +/- 0.9 h in fast acetylators, and 4.4 +/- 2.4 h in slow acetylators. This dependence on acetylator status was not seen in half life following oral administration. Total body clearance, steady state plasma procainamide and N-acetylprocainamide were not significantly dependent on acetylator status, although a few patients who are slow acetylators had unexpectedly low clearance and high steady state procainamide concentrations when given the higher dose.</description><subject>Biological Availability</subject><subject>Delayed-Action Preparations</subject><subject>Electrocardiography</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Kinetics</subject><subject>Procainamide - administration &amp; dosage</subject><subject>Procainamide - metabolism</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1978</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkL9PwzAQhS3Er1BYmBk6MSAF7mznUo9QUUCqxFLmyLHPaiBpit0K8d8T1Apuecun93SfEJcItwhQ3j3MAAoCXZgDkaFWMkfQeCgyAIU5mRJOxVlK7wBYGFAn4riUhiRkAhdLHq-XNnbW9R_NijeNS-M-jFPbf-WRW7ZpAGLvbLOyXeP5XBwF2ya-2OdIvM0eF9PnfP769DK9n-dOTnCTFxKRSEoOqEvS3jgssJSkSVlf64l2ktiHgiiQH27ijKqDMTJ4VRMaNRLXu95h_HPLaVN1TXLctnbF_TZV5fCmIcQBvNmBLvYpRQ7VOjadjd8VQvWrp_rXM8BX-9Zt3bH_Q3c-1A9cPF3P</recordid><startdate>19781201</startdate><enddate>19781201</enddate><creator>Tilstone, W J</creator><creator>Lawson, D H</creator><creator>Campbell, W</creator><creator>Hutton, I</creator><creator>Lawrie, T D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19781201</creationdate><title>The pharmacokinetics of slow-release procainamide</title><author>Tilstone, W J ; Lawson, D H ; Campbell, W ; Hutton, I ; Lawrie, T D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c281t-52116622ef14764d9c151726463adb484c26edf566f6dddd8c93bf992fd3b6193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1978</creationdate><topic>Biological Availability</topic><topic>Delayed-Action Preparations</topic><topic>Electrocardiography</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Kinetics</topic><topic>Procainamide - administration &amp; dosage</topic><topic>Procainamide - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tilstone, W J</creatorcontrib><creatorcontrib>Lawson, D H</creatorcontrib><creatorcontrib>Campbell, W</creatorcontrib><creatorcontrib>Hutton, I</creatorcontrib><creatorcontrib>Lawrie, T D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tilstone, W J</au><au>Lawson, D H</au><au>Campbell, W</au><au>Hutton, I</au><au>Lawrie, T D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The pharmacokinetics of slow-release procainamide</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1978-12-01</date><risdate>1978</risdate><volume>14</volume><issue>4</issue><spage>261</spage><epage>265</epage><pages>261-265</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Procainamide was given to 20 patients with normal renal function as an i.v. bolus of 500 mg followed by 1.0 or 1.5 g eight-hourly by mouth in the form of a slow release preparation (Durules). 97.6 +/- 27.1 (SD)% of the oral procainamide was absorbed, the absorption half life being 1.54 h. The elimination half life following the oral formulation was 6.0 +/- 0.8 h, compared to a mean of 3.4 +/- 0.4 h following i.v. administration. Elimination half life following i.v. administration was slightly related to acetylator status, being 2.75 +/- 0.9 h in fast acetylators, and 4.4 +/- 2.4 h in slow acetylators. This dependence on acetylator status was not seen in half life following oral administration. Total body clearance, steady state plasma procainamide and N-acetylprocainamide were not significantly dependent on acetylator status, although a few patients who are slow acetylators had unexpectedly low clearance and high steady state procainamide concentrations when given the higher dose.</abstract><cop>Germany</cop><pmid>729620</pmid><doi>10.1007/BF00560459</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-6970
ispartof European journal of clinical pharmacology, 1978-12, Vol.14 (4), p.261-265
issn 0031-6970
1432-1041
language eng
recordid cdi_proquest_miscellaneous_74329611
source MEDLINE; SpringerLink Journals
subjects Biological Availability
Delayed-Action Preparations
Electrocardiography
Half-Life
Humans
Kinetics
Procainamide - administration & dosage
Procainamide - metabolism
title The pharmacokinetics of slow-release procainamide
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T11%3A01%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20pharmacokinetics%20of%20slow-release%20procainamide&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Tilstone,%20W%20J&rft.date=1978-12-01&rft.volume=14&rft.issue=4&rft.spage=261&rft.epage=265&rft.pages=261-265&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/BF00560459&rft_dat=%3Cproquest_cross%3E74329611%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=74329611&rft_id=info:pmid/729620&rfr_iscdi=true